A trial looking at AT9283 for children and young people with acute leukaemia

The trial team were unable to find the best dose of AT9283 because of the low numbers of children who took part. As a result the trial closed early. 

This was a phase 1 trial. Everyone taking part had AT9283. The plan was for everyone to have AT9283 every 3 weeks. Each 3 week period is called a cycle of treatment.

The first few patients taking part had a low dose of AT9283. The next few patients had a higher dose and so on. This is called a dose escalation study.

This trial looked at 3 different doses of AT9283, a low, medium and higher dose.

• 3 children had a low dose of AT9283
• 3 children had the medium dose of AT9283
• 1 child had the higher dose of AT9283

All 7 children were withdrawn from the trial during or at the end of their first cycle of treatment because their leukaemia had started to grow again. So they did not have any further treatment with AT9283.   

The most common side effect reported were

• a drop in blood cells
• feeling or being sick

1 of the patients died during the trial. The doctors concluded that this was due to their leukaemia and not related to treatment with AT9283.

The trial team was not able to recommend a dose of AT9283 that could be used in future trials. It was not possible to find out whether AT9283 was useful for acute leukaemia because

• not enough patients took part.
• those who took part only had 1 cycle of treatment before their leukaemia started to grow again

We have based this summary on information from the research team. As far as we are aware, the information they sent us has not been reviewed independently (peer reviewed ) or published in a medical journal yet. The figures we quote above were provided by the research team. We have not analysed the data ourselves.